RT Journal Article
SR Electronic
T1 Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.11.20061994
DO 10.1101/2020.04.11.20061994
A1 Castro, Victor M
A1 Ross, Rachel A
A1 McBride, Sean M
A1 Perlis, Roy H
YR 2020
UL http://medrxiv.org/content/early/2020/08/28/2020.04.11.20061994.abstract
AB Objective Absent a vaccine or any established treatments for the novel and highly infectious coronavirus-19 (COVID-19), rapid efforts to identify potential therapeutics are required. We sought to identify commonly prescribed medications that may be associated with lesser risk of morbidity with COVID-19 across 6 Eastern Massachusetts hospitals.Design In silico cohort using electronic health records from individuals evaluated in the emergency department between March 4, 2020 and July 12, 2020.Setting Emergency department and inpatient settings from 2 academic medical centers and 4 community hospitals.Participants All individuals presenting to an emergency department and undergoing COVID-19 testing.Main Outcome or Measure Inpatient hospitalization; documented requirement for mechanical ventilation.Results Among 7,360 individuals with COVID-19 positive test results by PCR, 3,693 (50.2%) were hospitalized in one of 6 hospitals. In models adjusted for sociodemographic features and overall burden of medical illness, medications significantly associated with diminished risk for hospitalization included ibuprofen and sumatriptan. Among individuals who were hospitalized, 962(26.0%) were admitted to the intensive care unit and 608 (16.5%) died; ibuprofen and naproxen were also more commonly prescribed among individuals not requiring intensive care.Conclusions These preliminary findings suggest that electronic health records may be applied to identify medications associated with lower risk of morbidity with COVID-19, but larger cohorts will be required to address the substantial problem of confounding by indication, such that extreme caution is warranted in interpreting nonrandomized results.Trial Registration NoneSection 1: What is already known on this topic Absent a vaccine or any established treatments for the novel and highly infectious coronavirus-19 (COVID-19), rapid efforts to identify potential therapeutics are required.Section 2: What this study adds This cohort study across 6 hospitals identified medications enriched among individuals positive for COVID-19 who are less likely to experience adverse outcomes including hospitalization, intensive care, or death.Competing Interest StatementNo funding was received for this study. Dr. Perlis has received consulting fees from Burrage Capital, Genomind, RID Ventures, and Takeda. He holds equity in Outermost Therapeutics and Psy Therapeutics. Mr. Castro, Dr. Ross, and Dr. McBride report no conflict of interest.Funding StatementNo funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInstitutional review board approval does not allow sharing of identifiable data outside of the health system, but all analyses are provided as Supplemental Materials.